X4 Pharmaceuticals (XFOR) Receivables - Net (2020 - 2025)

X4 Pharmaceuticals (XFOR) posted Receivables - Net of $573000.0 for Q4 2025, down 35.69% on a QoQ basis from $891000.0 in Q3 2025, and down 46.45% year-over-year from $1.1 million in Q4 2024.

X4 Pharmaceuticals (XFOR) Receivables - Net (2020 - 2025) Analysis & Trends

X4 Pharmaceuticals' Receivables - Net history runs 3 years deep, the most recent figure standing at $573000.0 for Q4 2025.

  • Quarterly Receivables - Net fell 46.45% year-over-year to $573000.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $573000.0 (down 46.45% YoY) and the FY2025 annual result came in at $573000.0, down 46.45% from the prior year.
  • Receivables - Net was $573000.0 for Q4 2025 at X4 Pharmaceuticals, down from $891000.0 in the prior quarter.
  • Across five years, Receivables - Net topped out at $1.1 million in Q2 2025 and bottomed at $509000.0 in Q1 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Oculis Holding AG 66,621.14 Bn 66,620.85 Bn -
2 Nanobiotix 1,915.18 Bn 1,915.11 Bn -
3 Akari Therapeutics 1,014.18 Bn 1,014.18 Bn -
4 BeOne Medicines 471.27 Bn 466.48 Bn 1.35 Bn
5 Vertex Pharmaceuticals 121.81 Bn 114.57 Bn 2.59 Bn
6 Regeneron Pharmaceuticals 69.58 Bn 60.82 Bn 3.31 Bn
7 Belite Bio 62.72 Bn 62.72 Bn -
8 Argenx Se 55.51 Bn 50.33 Bn 1.41 Bn
9 Revolution Medicines 37.35 Bn 37.35 Bn -
10 X4 Pharmaceuticals 167.90 Mn -49.15 Mn 2.20 Mn

Historic Data

Download Data
DateValue
Dec 31, 2025 573,000.00
Dec 31, 2025 573,000.00
Sep 30, 2025 891,000.00
Sep 30, 2025 891,000.00
Jun 30, 2025 1.15 Mn
Jun 30, 2025 1.15 Mn
Mar 31, 2025 509,000.00
Mar 31, 2025 509,000.00
Dec 31, 2024 1.07 Mn
Dec 31, 2024 1.07 Mn
Sep 30, 2020 3.00 Mn
Sep 30, 2020 3.00 Mn
Jun 30, 2020 3.00 Mn
Jun 30, 2020 3.00 Mn
Mar 31, 2020 3.00 Mn
Mar 31, 2020 3.00 Mn